Drugs and Cosmetics Act, 1940

Imagine a rulebook written before India's independence still forming the legal foundation for every medicine sold in the country today, updated and amended repeatedly over eight decades, but never fully replaced. The Drugs and Cosmetics Act of 1940 is exactly that rulebook, the foundational law governing the import, manufacture, distribution and sale of drugs and cosmetics in India.

The Act establishes the basic legal architecture this entire industry operates within: what qualifies a substance as a drug requiring regulatory approval, the licensing requirements a manufacturer must meet, the quality standards a medicine must satisfy, and the penalties for manufacturing or selling spurious or substandard drugs. The Central Drugs Standard Control Organisation, CDSCO, along with individual state drug controllers, enforces the Act's provisions across manufacturing, import and sale.

The Act has been amended and supplemented extensively since 1940, most significantly through the New Drugs and Clinical Trials Rules of 2019, which modernised and consolidated India's clinical trial approval process, the same Phase I through Phase III framework already covered on this site, into clearer, faster, more internationally aligned timelines than the older, more fragmented rules it replaced.

This layered structure, an old foundational Act continuously modernised through newer rules rather than being scrapped and rewritten entirely, is a common pattern in Indian regulation, and it means understanding India's current pharma regulatory environment requires reading the 1940 Act's basic framework alongside far more recent rule updates like the 2019 clinical trial rules.

Whenever a drug manufacturer is prosecuted for producing spurious or substandard medicine, or a new drug's clinical trial approval process is discussed in regulatory terms, the Drugs and Cosmetics Act, and the rules issued under it, is the underlying legal foundation making that regulation, and its enforcement, possible at all.